Skip to main content

Month: April 2020

Champignon Secures Stable Psilocybin Supply Under DEA Schedule I License for TBI/PTSD Studies at the University of Miami

VANCOUVER, British Columbia, April 22, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to advance its clinical pipeline via a long-term supply of psilocybin for its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine. The Company is pleased to announce that its research partner and lead investigator, Dr. Michael Hoffer, has secured a sustainable supply of psilocybin under a DEA schedule I license, which will be used for ongoing psilocybin-based therapeutics studies.The psilocybin is to be provided by the same organization...

Continue reading

Aspo announces indicative tender offer results for its outstanding capital securities issued in 2016

ASPO Plc  INSIDE INFORMATION     April 22, 2020 at 10:00NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Aspo announces indicative tender offer results for its outstanding capital securities issued in 2016Aspo Plc (“Aspo” or the “Company” and together with its subsidiaries “Aspo Group”) announces the indicative results of its voluntary cash offer (the “Tender Offer”) to purchase its outstanding EUR 25 million 6.750 percent capital securities issued on May 27, 2016 (ISIN: FI4000210240) (the “2016 Capital Securities”).At the expiration deadline of the Tender Offer, 4:00 p.m. (Finnish time) EET on April 21, 2020, the aggregate nominal...

Continue reading

Aspo julkistaa vuonna 2016 liikkeeseenlasketun hybridilainan takaisinostotarjouksen alustavat tulokset

ASPO Oyj         Sisäpiiritieto             22.4.2020 klo 10.00EI JULKAISTAVAKSI TAI LEVITETTÄVÄKSI, SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA, HONGKONGISSA, JAPANISSA, UUDESSA-SEELANNISSA, SINGAPORESSA TAI ETELÄ-AFRIKASSA TAI SELLAISISSA MUISSA MAISSA TAI TÄLLAISIIN MAIHIN, JOISSA LEVITTÄMINEN TAI JULKAISEMINEN OLISI LAINVASTAISTA.Aspo julkistaa vuonna 2016 liikkeeseenlasketun hybridilainan takaisinostotarjouksen alustavat tuloksetAspo Oyj (”Aspo” tai ”Yhtiö” ja yhdessä tytäryhtiöidensä kanssa ”Aspo-konserni”) julkistaa alustavat tulokset tekemästään vapaaehtoisesta käteistarjouksesta (”Takaisinostotarjous”), jossa Yhtiö tarjoutui ostamaan takaisin 27.5.2016 liikkeeseen laskemansa 25 miljoonan euron 6,750 prosentin korkoisen hybridilainan (ISIN: FI4000210240) (”2016 Hybridilaina”).Takaisinostotarjouksen tarjousajan...

Continue reading

Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus

Hørsholm, Denmark (April 22nd, 2020) – Oncology Venture A/S (“OV” or the Company) today announced that it has entered into an agreement with the Pathogen and Microbiome Institute at Northern Arizona University (NAU) to test the antiviral activity of 2X-121, its PARP inhibitor, against Coronavirus.The cancer drug 2X-121 (formerly E7449) is a small molecule, targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in tumors, which was originally developed by the pharmaceutical company Eisai. 2X-121 is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.) using a DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.Recently, the PARP inhibitor, Mefuparib (CVL218), has...

Continue reading

Covid-19 : les retards de paiement des entreprises s’envolent de 56% en France selon le tracker Sidetrade-BFM Business

Un impact estimé à 75 Mds€ pour les entreprises en France Paris, France – 22 avril 2020 | Sidetrade, en partenariat avec BFM Business, publie le premier tracker sur les retards de paiement des entreprises. Ce tracker hebdomadaire s’appuie sur l’analyse statistique de 26 millions de factures totalisant 54 Mds d’euros de transactions inter-entreprises sur les principaux pays européens. Il suit l’évolution des comportements de paiement de plus de 3,7 millions d’entreprises, semaine par semaine. Pour la première fois, une étude approfondie lève le voile sur la réalité des factures impayées. Sans surprise, la part des factures impayées s’envolent de 56% en France depuis que les mesures de confinement sont entrées en vigueur.Dans le contexte actuel de crise sanitaire doublée d’une crise économique historique, comment se comportent les entreprises...

Continue reading

MSAB publicerar årsredovisning för 2019

MSABs årsredovisning för 2019 finns nu tillgänglig på bolagets hemsida, www.msab.com/investerare/finansiella-rapporter/, samt bilagt detta pressmeddelande. Tryckt version kommer att finnas tillgänglig inom kort och kan beställas hos bolaget per telefon + 46 (0) 8 739 02 70 eller per e-post info@msab.com.Frågor ställs till:Verkställande direktör Joel Bollö, tel. 08-739 02 70, e-mail: joel.bollo@msab.comDenna information är sådan som MSAB, 556244-3050, är skyldigt att offentliggöra enligt EU:s marknadsmissbruks-förordning. Informationen lämnades, genom nedanstående kontaktpersons försorg, för offentliggörande den  22 april 2020 klockan 08:30 CEST.Kort om MSAB

Continue reading

Belships ASA : Notice of Annual General Meeting

Notice of Annual General Meeting and attendance form/proxy form are enclosed and will also be made available on www.belships.com.The notice will be sent to all shareholders with known address.The Annual General Meeting will be held at the Company’s premises at Lilleakerveien 4, Oslo on Thursday 14 May 2020 at 10.00 a.m.AttachmentBelships ASA – Notice of Annual general meeting

Continue reading

Belships ASA : Innkalling til ordinær generalforsamling

Vedlagt er innkalling m/vedlegg til selskapets ordinære generalforsamling torsdag 14. mai 2020 kl. 10.00 i selskapets lokaler i Lilleakerveien 4, Oslo.Innkallingen vil bli sendt til alle selskapets aksjonærer med kjent adresse, og kan også lastes ned fra selskapets hjemmeside www.belships.com.VedleggBelships ASA – Innkalling til ordinær generalforsamling 2020

Continue reading

MARCH 2020 QUARTERLY REPORT CONFERENCE CALL

PERTH, Western Australia, April 22, 2020 (GLOBE NEWSWIRE) — Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) ”) is hosting a conference call to discuss its March 2020 Quarterly Report, which is anticipated for release around 8.30am AEST on Tuesday April 28, 2020.Call Details Australia: Tuesday April 28, 2020 (Perth – 7:00am) (Sydney/Melbourne – 9:00am)Canada: Monday April 27, 2020(Toronto – 7:00pm)(Vancouver – 4:00pm)UK: Tuesday April 28, 2020(London – 12:00am)Listen online: https://services.choruscall.com.au/webcast/perseus-200428.htmlAudio access dial in numbers:Australia: 1800 908 299Hong Kong: 800 968 273Singapore: 800 101 2702USA/Canada: 1855 624 0077New Zealand: 0800 452 795United Kingdom: 0800 051 1453To join the conference call, please ask the operator to be connected to the Perseus Mining call.The...

Continue reading

CellaVision AB: Stable start of the year with good growth in APAC

The information was submitted for publication at 08.20 CET on April 22, 2020January 1 – March 31, 2020Net sales increased by 29 % to SEK 134.4 million (103.9).Sales grew organically by 1 % (31).EBITDA increased to SEK 41.2 million (38.3).EBITDA margin was 31 % (37).Profit before tax was SEK 25.5 million (34.8).Earnings per share before and after dilution were SEK 0.85 (1.15).Cash flow from operating activities was SEK 15.4 million (51.1).Significant events due to COVID-19Due to the COVID-19 has the Board of Directors withdrawn the original dividend proposal and proposes instead that no dividend be paid for 2019 (SEK 1.50 / share) at the Annual General Meeting 2020 (AGM).The company expects the COVID-19-pandemic to have a significant negative impact on CellaVision’s sales and earnings for a number of months.In accordance with the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.